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Abstract: Derivatives of 3,4-hydroxypyridinones have been extensively studied for in vivo Fe3+
sequestration. Deferiprone, a 1,2-dimethyl-3,4-hydroxypyridinone, is now routinely used for clinical
treatment of iron overload disease. Hexadentate tris(3,4-hydroxypyridinone) ligands (THP) complex
Fe3+ at very low iron concentrations, and their high affinities for oxophilic trivalent metal ions
have led to their development for new applications as bifunctional chelators for the positron
emitting radiometal, 68Ga3+, which is clinically used for molecular imaging in positron emission
tomography (PET). THP-peptide bioconjugates rapidly and quantitatively complex 68Ga3+ at ambient
temperature, neutral pH and micromolar concentrations of ligand, making them amenable to
kit-based radiosynthesis of 68Ga PET radiopharmaceuticals. 68Ga-labelled THP-peptides accumulate
at target tissue in vivo, and are excreted largely via a renal pathway, providing high quality
PET images.
Keywords: hydroxypyridinone; deferiprone; gallium; iron overload; positron emission tomography;
molecular imaging; bifunctional chelators
1. Introduction
Positron emission tomography (PET) is a whole body diagnostic three-dimensional molecular
imaging modality used in nuclear medicine that detects radiation arising from the decay of unstable
positron-emitting radioisotopes. The availability of the positron-emitting isotope, gallium-68 (68Ga)
from decay of 68Ge in a bench top 68Ge/68Ga generator is likely to have significant clinical impact on
the use of PET for molecular imaging [1]. Clinical use of 68Ga receptor-targeting radiopharmaceuticals
for neuroendocrine cancers (68Ga-DOTA-TATE) [2] and prostate cancers (68Ga-HBED-PSMA) [3] has
changed patient management in centres that have routine access to such agents. 68Ga molecular
imaging agents typically consist of chelators tethered to a receptor-targeted peptide, protein or small
molecule. As Ga3+ can incorporate up to six ligands in an octahedral coordination sphere, hexadentate
ligands are normally utilised. The Ga3+ ion has a high charge density, and is categorised as a “hard”
Lewis acid, and so the majority of hexadentate ligands incorporate oxygen and/or nitrogen donor
atoms. Both macrocyclic and acyclic chelators have been explored for 68Ga3+ complexation [1,4–7].
Clinical radiosyntheses of 68Ga-DOTA-TATE and 68Ga-HBED-PSMA involve heating at 80–100 ◦C
for 5–20 min at pH 3–5 [1,4], followed by post-synthetic purification and work-up to remove impurities,
unreacted 68Ga and reaction components that are not physiologically compatible. In the case of
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68Ga-DOTA-TATE, heating is required for complexation of 68Ga3+. For 68Ga-HBED-PSMA, three
geometric cis/trans isomers are possible, with each possible geometric isomer having a diastereomer.
In this case, heating the reaction favours formation of the thermodynamically preferred species.
For 68Ga to be adopted in routine clinical practice, chelators that provide efficient and reproducible
kit-based radiolabelling methods—preferably a single manipulation—are required. The chelators that
we have developed based on hydroxypyridinones allow one-step quantitative 68Ga3+ radiolabelling at
neutral pH and ambient temperature.
Hydroxypyridinone (HP) ligands have high affinities for “hard” metal ions, and originally, the
class of HPs described herein was developed extensively for therapeutic in vivo Fe3+ chelation in iron
overload disease [8–10]. The bidentate HP ligand, deferiprone (1, Figure 1), is used routinely for this
treatment [11]. Through chemical modification of substituents, Fe3+ affinity, hydrophilicity, metabolic
stability and functionality of HPs can be tailored [10].
Ga3+ is an oxophilic metal ion, with a high charge density and ionic radius and coordination
preferences similar to Fe3+. The (crystal) ionic radius for Ga3+ is 76 pm, and for high spin Fe3+ is
78.5 pm [12]. Recently, we have investigated the use of HPs for rapid and quantitative chelation
of 68Ga3+ (as well as a long-lived PET isotope, 89Zr4+) and adapted a class of HPs to enable
functionalisation with peptides and proteins for targeted molecular imaging [13–16].
Here we describe our research on the development of HPs for Fe3+ chelation, and how the design
of such chelators is suitable for direct translation to 68Ga PET radiopharmaceuticals. It is not intended
as an exhaustive review of chelators for either treatment of iron overload disease or complexation of
radioisotopes of gallium used in nuclear medicine. The literature in both areas has been surveyed in
depth in recent years in several excellent reviews and books [4–7,10,17–19].
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Figure 1. Deferiprone (1): Resonance structures at different protonation states [20]. 
2. Hydroxypyridinones 
HPs consist of a six-membered aromatic N-heterocycle, with a hydroxyl and a ketone 
functionality. Varying relative positions of the hydroxyl and ketone functional groups within a 
bidentate HP molecule results in three types of hydroxypyridinones: 1,2-hydroxypyridinone (2); 
3,2-hydroxypyridinone (3); and 3,4-hydroxypyridinone (4) (Figure 2). Neutral HPs can be 
protonated and deprotonated, with the first pKa typically corresponding to 
protonation/deprotonation at the oxo group, and the second, at the hydroxyl group. Delocalisation 
of the electrons of the N1 ring atom leads to aromaticity (Figures 1 and 2). 
When HPs are deprotonated at the hydroxyl group, they are capable of complexing metal ions 
in a bidentate O2 mode, forming five-membered chelate rings. The relative positions of the hydroxyl 
and ketone groups, as well as ring substituents, influence pKa values and metal binding affinities. In 
general, pKa (the negative logarithm of the acid dissociation constant) and metal ion affinity values 
(both stepwise and cumulative stability constants of the metal-chelator complex) follow the order 
3,4-HP > 3,2-HP and 1,2-HP (Table 1). This order reflects the relative decrease in delocalisation of the 
N1 atom lone pairs over the ring, and a corresponding decrease in charge density on the O atoms. 
Figure 1. Deferiprone (1): Resonance structures at different protonation states [20].
2. Hydroxypyridinones
HPs consist of a six-membered aromatic N-heterocycle, with a hydroxyl and a ketone functionality.
Varying relative positions of the hydroxyl and ketone functional groups within a bidentate HP molecule
results in three types of hydroxypyridinones: 1,2-hydroxypyridinone (2); 3,2-hydroxypyridinone (3);
and 3,4-hydroxypyridinone (4) (Figure 2). Neutral HPs can be protonated and deprotonated, with the
first pKa typically corresponding to protonation/deprotonation at the oxo group, and the second, at the
hydroxyl group. Delocalisation of the electrons of the N1 ring atom leads to aromaticity (Figures 1
and 2).
When HPs are deprotonated at the hydroxyl group, they are capable of complexing metal ions
in a bidentate O2 mode, forming five-membered chelate rings. The relative positions of the hydroxyl
and ketone groups, as well as ring substituents, influence pKa values and metal binding affinities.
In general, pKa (the negative logarithm of the acid dissociation constant) and metal ion affinity values
(both stepwise and cumulative stability constants of the metal-chelator complex) follow the order
3,4-HP > 3,2-HP and 1,2-HP (Table 1). This order reflects the relative decrease in delocalisation of the
N1 atom lone pairs over the ring, and a corresponding decrease in charge density on the O atoms.
Int. J. Mol. Sci. 2017, 18, 116 3 of 23
The measurement of pM (negative logarithm of free metal concentration) is a more useful comparative
measure for chelators than log Ka or affinity constants, as pM accounts for ligand basicity, denticity
and protonation. Measurements are typically obtained at pH 7.4, with [total ligand] = 10−5 M and
[total metal ion] = 10−6 M. Derivatives of high affinity 3,4-HPs have been extensively studied for
iron-overload disease, and generally, 3,4-HPs have higher pM values than homologous 3,2- and
1,2-HPs. Additionally, 3,4-HPs are neutral at physiological pH, and when appropriately functionalised,
can cross cell membranes.
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Table 1. Protonation constants, stepwise stability constants (log K) and cumulative Fe3+ stability 
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3,4-HP (4) 3.34 9.01 14.2 11.6 9.3 35.1 [23] 
3.60 9.60 – – – 36.9 [20] 
3,4-HPs have high affinity for both Fe3+ and Ga3+, and form neutral 3:1 bidentate complexes with 
Fe3+ and Ga3+ (Figure 3, Table 2) (as well as Al3+, In3+, Cr3+, Mn3+ and Gd3+) [24–31]. Both the 
[Fe(deferiprone)3] and [Ga(deferiprone)3] complexes crystallise in the same octahedral geometries 
with comparable bond lengths and angles. In the three coordinating deferiprone ligands in both 
complexes, O3 atoms are fac to each other (see Table 3 for atom numbering scheme). Fe–O3 bond 
lengths are 1.998 Å, and Fe–O4 bond lengths, 2.038 Å while in the Ga analogue the corresponding 
Ga–O bond lengths are 1.967 Å, and 1.990 Å, respectively. In both complexes, both C–O bonds are 
intermediate between single and double bonds, with the C4–O4 bond shorter than the C3–O3 bond. 
Within each deferiprone ligand, bond angles are 80.91° for O3–Fe–O4, and 83.22° for O3–Ga–O4. Other 
metal ions (M = Al3+, In3+, Cr3+, Mn3+) form isostructural [M(deferiprone)3] complexes [27–30], and in 
all cases, fac geometries are observed in the solid state. However, 1H NMR studies on diamagnetic 
Ga3+ and Al3+ complexes suggest that conversion between fac and mer geometric isomers occurs in 
solution [30]. 
Figure 2. Resonance structures of 1,2-HP, 3,2-HP and 3,4-HP [21].
Table 1. Protonation constants, stepwise stability constants (log K) and cumulative Fe3+ stability
constants (log β3) for 1,2-HP, 3,2-HP and 3,4-HP.
Compound pKa1 pKa2 log K1 log K2 log K3 log β3 Fe3+ Ref.
1,2-HP (2)
1.2 5.86 10.6 9.5 7.1 27.2 [22]
−0.9 5.78 10.3 9.0 7.6 26.9 [23]
3,2-HP (3) 0.1 8.66 11.7 9.8 8.1 29.6 [23]
3,4-HP (4)
3.34 9.01 14.2 11.6 9.3 35.1 [23]
3.60 9.60 – – – 36.9 [20]
3,4-HPs have high affinity for both Fe3+ and Ga , a d form neutral 3:1 bidentate complexes with
Fe3+ and Ga3+ (Figure 3, Table 2) (as well as Al3+, In3+, Cr3+, Mn3+ and Gd3+) [24–31]. Both the
[Fe(deferi rone)3] [31] and [Ga(deferiprone)3] [29] complexes crystallise in the same octahedral
geometri with c parable bond lengths and angles. In the three coordinat def riprone ligands in
both complexes, O3 atoms are fac t each other (see Table 3 for atom numberin scheme). F –O3 bo d
lengths are 1.998 Å, nd Fe–O4 bo lengths, 2.038 Å while in the Ga analogue the corresponding
Ga–O bond lengths are 1.967 Å, and 1.990 Å, respectively. In both complex s, both C–O bonds are
intermediate between single and double bonds, with the C4–O4 bond shorter than the C3– 3 bond.
Within each deferipro e ligand, bond angle are 80.91◦ for O3–Fe–O4, and 83.22◦ for O3–Ga–O4.
Other met l ions (M = Al3+, In3+, Cr3+, Mn3+) f rm isostructural [M(deferiprone)3] complexes [27–30],
and in all cases, fac g ometri are observed i the solid st te. How ver, 1H NMR tudies o
diamagnetic Ga3+ and Al3+ complexes suggest that conversion between fac and mer geometric isomers
occurs in solution [30].
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In living organis s, iron plays an essential role in transport of oxygen, electron transfer, and
activation and functioning of enzy es. Iron transport and etabolis are tightly controlled in living
organis s. In patients ith iron overload disease, a disruption to iron ho eostasis results in “free”
iron, largely present as a citrate-albumin complex [32]. This iron pool gives rise to Fenton redox cycling
between Fe2+ and Fe3+, producing free radicals that result in toxic tissue damage [33]:
Fe2+ + H2O2 → Fe3+ + HO· + OH− (1)
Fe3+ + H2O2 → Fe2+ + HOO· + H+ (2)
Therapeutic chelators, including 3,4-HPs are clinically used for sequestration of Fe3+
in vivo [7–10]. 3,4-HPs can be functionalised at the N1, C2, C5 or C6 positions of the ring (Table 3).
An understanding of he effects of substitution is critical in optimizing 3,4-HP derivatives for either
therapeutic Fe3+ chelation, or radiopharmaceutical Ga3+ chelation.
Table 2. Prot ation constants and Fe3+ and Ga3+ stability constants for deferiprone (1) (measured t
22.5–25 ◦C, ionic strength 0.1–0.2 M; for pM values, pH 7.4, with [total ligand] = 10−5 M and [total
metal ion] = 10−6 M).
Metal Ion pKa1 pKa2 log K1 log K2 log K3 log β3 pM3+ Ref.
Fe3+
3.56 9.64 14.92 12.23 9.79 37.2 – [20]
3.68 9.77 14.56 12.19 9.69 36.4 19.4 [34]
3.62 9.76 15.14 11.54 9.24 35.92 18.3 [35]
– – 15.1 11.51 9.27 35.88 – [25]
3.61 9.78 15.03 27.42 – 37.35 20.74 [36]
Ga3+
– – 13.17 12.26 10.33 35.76 – [25]
3.70 9.86 17.07 12.19 9.16 38.42 – [37]
3. 3,4-Hydroxypyridinones for Fe3+ Complexation
3.1. Tailoring 3,4-HP Properties by Ring Substitution
Substitution at the C2 position results in pronounced effects on metal ion affinity. Alkylation
increases pyridinone ring electron density, and increases pKa values and log K and log β3(Fe3+) constants
(log β3 = 35.1 when R2 = H (4); log β3 = 37.2 when R2 = CH3 (5)) [20], although pFe3+ values are not
markedly affected [26].
Int. J. Mol. Sci. 2017, 18, 116 5 of 23
Substitution of C2 alkyl groups for 1′-hydroxyalkyl groups decreases pKa and log β3(Fe3+) constants
(compare 1 with 6; and 7, 8 and 9) [34]. This decrease in affinity is a result of: (i) a decrease
in ring electron density due to a negative induction effect of the C2 1′-hydroxylalkyl group; and
(ii) intramolecular hydrogen bonding between the C2 1′-hydroxyalkyl group and the deprotonated
C3 hydroxyl group (Figure 4). This hydrogen bonding stabilises the ionised C3 hydroxyl group.
However, although Fe3+ affinity is decreased, the concurrent lowering of pKa2 actually results in an
increase in pFe3+. The decrease in proton affinity favours the negative form that coordinates to Fe3+.
In a side-by-side comparison at pH 7.4, pFe3+ values of the C2 1′-hydroxyalkyl derivatives are higher
than C2 alkyl derivatives [34].
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Figure 4. Intramolecular hydrogen bonding can stabilise ionised hydroxyl groups of 3,4-HPs.
Similar effects are also observed upon introduction of a C2 amido group (Figure 4) [38].
A combination of a negative induction effect and hydrogen bonding from the C2 amido NH to
the C3 hydroxyl group decreases Fe3+ stability constants, but the concurrent decrease in pKa serves to
increase pFe3+ values at physiological pH relative to C2 alkyl derivatives. The C2 doubly alkylated
N(CH3)2 amido group of 10 cannot form a hydrogen bond with the C3 hydroxyl group (Figure 4), and
so its pFe3+ value is lower when compared to 11 bearing a singly alkylated NH(CH3) that can form
a hydrogen bond (Table 3) [38].
In contrast to C2, varying alkyl substituents at the N1 position (H, methyl, ethyl) of 3,4-HP does
not markedly affect the proton or metal ion affinity of 3,4-HPs (compounds 1, 5, 12 in Table 3) [20].
The exception to this is the C2 amido derivatives discussed above, where N1 alkylation sterically
inhibits coplanarity of the C2 amido group with the HP ring, disrupting hydrogen bonding and thus
decreasing pFe3+ values [38]. As such, N1 alkyl substitution can be a useful strategy for tailoring
chelators’ lipophilicity, cell permeability [20], in vivo biodistribution [34], and rates of metabolism [39]
without deleterious effects on metal ion affinity. Substitution at N1 sites has also been utilised to
functionalise 3,4-HPs with fluorescent tags [40] or biological vectors [41].
Alkyl substitution at the C5 position increases 3,4-HP affinity for Fe3+, however as there is
a concurrent increase in pKa2, pFe3+ does not increase relative to derivatives that do not contain a C5
alkyl group (compounds 13 and 14) [36]. There are no studies directly comparing and quantifying the
effect of C6 substitution, but existing data of C6 methylated derivatives suggest that alkylation has
little influence on 3,4-HP metal affinity [36].
Increasing the lipophilicity of 3,4-HPs increases their cell membrane permeability.
Higher intracellular 3,4-HP accumulation results in greater intracellular Fe3+ scavenging, however
excessive cellular uptake of 3,4-HPs results in toxicity [20]. A prodrug strategy that involves oral
administration of an N1-substituted hydrophobic ester 3,4-HP (15, Figure 5) has proved particularly
successful in scavenging iron in a preclinical iron overloaded rat model [34]. In iron overload disease,
excess iron is stored in the liver, and the rat model mimics this. The ester compound 15 is absorbed
effectively in the gastrointestinal tract, and delivered to the liver, where it enters target iron-overloaded
hepatocyte cells. The compound is proposed to undergo ester hydrolysis and metabolism intracellularly
(16, 17) prior to complexing Fe3+ [20]. The complex is then excreted, recovering excess iron from
diseased animals efficiently. In contrast, when the more hydrophilic N1 propyl alcohol derivative 16
(Figure 5) is directly administered to rats, absorption is less effective, and Fe3+ recovery is lower.
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Figure 5. Schematic representation of the use of hydrophobic esters to enhance both the absorption
from the gastrointestinal tract (GIT) and the hepatic extraction of the chelator. Subsequent intracellular
hydrolysis occurs yielding a hydrophilic chelator which can undergo further metabolism to the
extremely hydrophilic negatively charged 1-carboxyalkyl metabolite in the liver. Reprinted with
permission from Liu, Z.D.; et al. Synthesis, physicochemical characterisation, and biological evaluation
of 2-(1′-hydroxyalkyl)-3-hydroxypyridin-4-ones: Novel iron chelators with enhanced pFe3+ values.
J. Med. Chem. 1999, 42, 4814–4823. Copyright American Chemical Society.
Table 3. Protonation constants and Fe3+ stability constants for 3,4-HP derivatives.
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3.2. Deferiprone, Desferrioxamine and Deferasirox
Deferiprone (or Ferriprox) (1), developed by Hider and colleagues, has been clinically approved
(in Europe in 1999, and the USA, in 2011) for treatment of iron overload diseases, including
hemochromatosis and tr nsfusion-dependant thalassemia [42]. The advantage of deferiprone is
that it is both orally active and effective at sequestering Fe3+ from the blood stream, heart (where iron
overload toxicity can be fatal) and liver (where excess iron is stored).
Two other approved treatments for iron overload are available. The first is the hexadentate
hydroxamate chelator, desferrioxamine-B (DFO, 18, Figure 6), which forms a co plex with Fe3+ with
Int. J. Mol. Sci. 2017, 18, 116 7 of 23
a metal to ligand stoichiometry of 1:1 and an overall charge of +1 under physiological conditions.
DFO requires parenteral infusion over 8–12 h, several times a week, as it is not orally absorbed [42].
Clinical studies have demonstrated that either deferiprone alone, or a combination of deferiprone
and DFO, are more effective therapies for myocardial iron overload than DFO alone. Additionally,
a combination of oral deferiprone and parenteral DFO therapies is more viable for patients than
parenteral DFO therapy alone, as combination therapy results in fewer parenteral infusions.
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Like deferiprone, deferasirox [43] (19, Figure 6) is an effective orally active treatment for iron
overload with clinical approval (in Europe in 2006 and the USA in 2005). It is a tridentate ch lator,
with Fe3+ complexes bearing a 3-charge at physiological pH. Data from clini al comparisons of the
efficacy of deferiprone and deferasirox are conflicting and inconclusive, possibly due to variations in
doses of the two treatments [44–47]. Some clinical data suggest that d feriprone is more effective at
reducing ir levels in cardi c tissue [46,47].
3.3. Synthesis of 3,4-HPs
The structural diversity of 3,4-HPs is a result of extensive synthetic research that spans several
decades. It is beyond the scope of this review to describe all of these synthetic routes in great detail,
but it is worth highlighting common starting routes, and routes that give rise to N1- and C2-substituted
3,4-HPs that are important precursors for new, bioactive compounds.
Pyranones such as maltol (20) containing a benzyl (Bn) protecting group can simply be converted
to pyridinones by reaction with primary amines (Scheme 1) [20]. This allows diverse substitution at
N1, including incorporation of reactive groups such as carboxylates or primary amines that lead to
further functionalization [20,40].
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Scheme 1. Synthetic route for N1-substituted 3,4-HPs.
Compound 22 is a pyranone containing a Bn protecting group, and a reactive alcohol. It is a key
synthetic precursor enabling versatile manipulation of functionality at the C2 position of 3,4-HPs
(Scheme 2). It is synthesised in high yields from the commercially available and inexpensive precursor,
kojic acid (21) in four steps [48,49]. As discussed above, the Bn-protected 22 can be converted to
Bn-protected pyridinone 23 by reaction with methylamine [49]. Protection of the ethyl alcohol group
(and subsequent deprotection) increases yields in this reaction. A Mitsunobu reaction of 23 with
phthalamide gives a Bn-protected pyridinone (24) that contains a phthalamide at the C2 position, that
can be simply converted to a primary amine (25) [49]. Bn-protected 25 is a very useful precursor for
preparation of tris(hydroxypyridinones) such as 26 (see below).
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Scheme 2. Synthesis of a useful 3,4-HP with a reactive amine (25) that is used for synthesis of THP-Ac (26).
Alternatively, 22 can be converted at the alcohol to a carboxylic acid in two steps to give pyranone
27 (Scheme 3) [48]. Compound 27 can then be coupled with 2-mercaptothiazoline using appropriate
reagents to give pyranone 28 that contains an active amide. Compound 28 can be reacted with primary
or secondary amines, resulting in pyranone amide derivatives that can be converted to Bn-protected
pyridinones by reaction with methylamine or ammonia [38,48]. For example, Bn-protected precursors
to compounds 10 and 11 are prepared in this fashion.
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Reactive carboxylates are synthetically accessible from Bn-protected pyridinones (Scheme 4) [50].
Bn-protected 29 can be further protected, and the methyl group substituted to ultimately yield 30.
Compound 30 can be converted to a carboxylate, yielding 31. The carboxylate group of 31 can be
further activated with an N-hydroxysuccinimide if required (32). Such derivatives have been used to
prepare tris(hydroxypyridinones) such as 33 and 34 as well as other amide derivatives (35) [50].
Deprotection of Bn-protected hydroxyl groups proceeds via either hydrogenation reactions
(catalysed by palladium on carbon) followed by acidification, or treatment with dissolved boron
trichloride in an aprotic solvent, followed by addition of an alcohol (Schemes 1, 2 and 4).
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4. Hexadentate Tris(hydroxypyridinone) Ligands
4.1. Topology and Fe3+ Affinity
Incorporation of three bidentate 3,4-HP ligands into a tripodal construct provides hexadentate
tris(hydroxypyridinone) ligands (THPs) that, in a suitably designed scaffold, saturate the coordination
sphere of octahedral metal ions. THPs have been designed for applica ions n gastrointestinal
scavenging of Fe3+ [51], ant microbial activi y (via deprivation of m crobes’ Fe3+ pool) [52,53], and
fluorescence imaging of cellular Fe3+ distribution [54]. The topology of tripodal THPs is critically
important to formation of octahedral complexes with 1:1 stoichiometry. The backb n of the tripod
should be connected ortho to a coordinating O atom [55].
The synthesis of the first generation of THP ligands utilised 3,4-HP groups with a C2 carboxylate
substitution (32), allowing reaction with tripodal polyamines to yield compounds such as 33 and
34 (Scheme 4). In 33 and 34, 3,4-HP units are attached via a C2 amide group, and fulfil the
topology requirements outlined above for formation of hexadentate compounds with 1:1 stoichiometry.
For compound 34, log K1 = 30.7, whereas for the bidentate homologue 35, log β3 = 31.4 [50]. In this case,
the affinity of the bidentate 3,4-HP for Fe3+ is already optimal, and incorporation into a hexadentate
form does not result in an increase in thermodynamic stability, as might normally be expected for
an increase in ligand denticity and accompanying lower entropic costs. The pFe3+ of 34 (30.5 at
pH 7.4) is higher than the pFe3+ of 35 (22.0) [50]. This arises because the formation constant of a
hexadentate complex of 34 has only a first order dependence on ligand concentration (1:1 ligand
to metal stoichiometry), whereas that of 35 necessarily has third order dependence on free ligand
concentration (3:1 ligand to metal stoichiometry). In solutions of 34 where the hexadentate ligand
concentration = 10 µM, the total concentration of single 3,4-HP units is three times greater than in
solutions of 35 where the biden te ligand concentration = 10 µM.
Instead of polyamine tripods, he next ge eration f THP ligands derivatised tripodal carboxylate
groups, using 3,4-HP units wi h a C2 aminomethyl substituent (25, Scheme 2) [51]. In the resulting
compounds, fo example THP-Ac (26, Scheme 2), each 3,4-HP group is tethered to the tripod via
an amidomethyl linker at the C2 position. The N1 and C6 positions are methylated. Wit the exception
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of C6-methylation, THP-Ac’s single 3,4-HP unit is structurally similar to deferiprone. For THP-Ac, log
K1 = 32.52 and pFe3+ = 28.47 [51].
The incorporation of three 3,4-HP groups into a tripodal ligand also has implications for the
lability of hexadentate complexes. For example, in [Fe(THP-Ac)], dissociation of a single 3,4-HP unit is
likely to be followed by its rapid recoordination to the metal centre. During dissociation, this 3,4-HP
unit will remain spatially close to the metal centre, as the other two 3,4-HP groups, to which it is
covalently tethered, are likely to still be bound to Fe3+. On the other hand, in [Fe(deferiprone)3], if a
deferiprone ligand dissociates, it has a lower probability of recoordinating to the same metal centre, as
it is not anchored to any other coordinating ligands. The activation energy barrier to dissociation of
[Fe(THP-Ac)] is higher than that of [Fe(deferiprone)3], and [Fe(THP-Ac)] is more kinetically inert than
[Fe(deferiprone)3].
4.2. Dendrimers Based on THP Units
Dendritic THP molecules, for example 36, have incorporated between three and six THP groups,
allowing coordination of between three and six equivalents of coordinatively saturated Fe3+ per
molecule [51,56]. Dendrimers have been prepared from both 25 and 32. Affinity constants as well as
pFe3+ values of dendrimer 36 (Figure 7) (log K1 = 32.74, pFe3+ = 28.69) and other derivatives do not
meaningfully deviate from values for the single THP-Ac homologue 26, indicating that maximum Fe3+
binding efficiency is achieved using 3,4-HP motifs in a tripodal THP topology.
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4.3. Derivatising THP Ligands
THP compounds of the same topology and substitution as THP-Ac (26) are synthetically accessible
from the β-alanine derivative, THP-NH2 (37, Figure 8) using similar reaction routes to that described
in Scheme 2 [51]. THP derivatives such as 33 or 34 are less amenable to derivatisation in this fashion.
The presence of an apical primary amine in THP-NH2 allows attachment to dendritic scaffolds [51],
biomolecules [13–16], polymer units [57], and fluorophores [54]. This ability to functionalise THP
compounds makes them attractive for technological applications where trivalent metal ion complexes
of high affinity and kinetic stability are required. We have explored THP derivatives for PET imaging
with Ga3+.
Int. J. Mol. Sci. 2017, 18, 116 11 of 23
Int. J. Mol. Sci. 2017, 18, 116 11 of 23 
 
 
Figure 8. THP derivatives. 
5. Tris(hydroxypyridinone) Ligands for Radiolabelling with 68Ga3+ 
5.1. Radiolabelling Peptides with 68Ga for PET Imaging: The Case for Tris(hydroxypyridinone) Derivatives 
Peptide-based molecular imaging agents can rapidly accumulate at target tissue and clear from 
circulation within 1–2 h. The 68 min half-life and positron emission properties of 68Ga (β+ 90%,  
Emax = 1880 KeV) match these requirements for PET imaging of peptide receptor expression. 
Moreover, 68Ga is conveniently available by elution of the 68Ge/68Ga generator to produce 
no-carrier-added solutions of 68Ga3+ in hydrochloric acid [58]. 
Hydrated Ga3+ species such as [Ga(H2O)6]3+ exist in aqueous solution below pH 4. As the pH is 
raised above 4, the poorly soluble hydroxide species Ga(OH)3 predominates in solution, until pH > 
6.3, where tetradentate [Ga(OH)4]− predominates [59,60]. For efficient 68Ga3+ radiolabelling of 
chelate-peptide conjugates at neutral or near neutral pH, chelate complex formation must effectively 
compete with unreactive 68Ga-colloid formation. Preferably, the rate of chelation will be 
diffusion-controlled, so that complex formation outcompetes 68Ga3+ colloid formation. Additionally, 
the amounts of 68Ga eluted from clinical generators are in the range of 200–2000 MBq, approximately 
equivalent to 2–20 pmol of 68Ga3+ in 1–5 mL of solution. Highly efficient chelators are required to 
quantitatively complex such low concentrations of metal ion without using excessively high chelator 
concentration. In clinical formulations of chelator bioconjugates, low concentrations of 
chelator-peptide conjugate are important. Clinical formulations do not usually separate unlabelled 
bioconjugate from labelled conjugate, and large amounts of unlabelled conjugate can lead to saturation 
of target receptors in vivo. 
As THP ligands have extraordinarily high pFe3+ values, and Ga3+ has similar coordination 
preferences to Fe3+, it was reasoned that such chelators could be very efficient at quantitatively 
coordinating 68Ga3+ at low chelator concentrations [13]. The acyclic nature of THP, and hence 
flexibility compared to macrocyclic ligands, results in low activation barriers to complexation, 
resulting in rapid rates of reaction at room temperature. 
It is also critical that the 68Ga3+ complex is sufficiently kinetically stable over the period of time 
required for imaging (1–2 h) to withstand transchelation by competing endogenous proteins, such as 
transferrin, and other ligands that compete for Ga3+ in vivo [4]. The iron transport protein transferrin 
is abundant in serum and its two metal binding sites have high affinity for Fe3+ (log β1 = 22.8, log β2 = 
44.3) and Ga3+ (log β1 = 20.3, log β2 = 39.6) [61]. Transchelation of 68Ga3+ to endogenous ligands results 
in increased non-target tissue uptake and lower tumour/diseased tissue uptake, decreasing PET 
image quality. 
As 3,4-HP and THP derivatives can bind Fe3+ under physiological conditions, with the resulting 
complexes excreted, it was hypothesised that a THP Ga3+ complex could be sufficiently stable in 
vivo. Mouse biodistribution studies with the γ-emitting isotope, 67Ga3+ (half-life = 78 h), comparing 
the biodistribution of [67Ga(deferiprone)3] with [67Ga(citrate)3] show that mice administered the 
deferiprone complex intravenously have lower 67Ga blood activity one day post-administration than 
animals administered the citrate complex [37]. Subsequent studies demonstrate that 67Ga: (i) clears 
more rapidly from animals administered the deferiprone complex compared to animals 
Figure 8. THP derivatives.
5. Tris(hydroxypyridinone) Ligands for Radiolabelling with 68Ga3+
5.1. Radiolabelling Peptides with 68Ga for PET Imaging: The Case for Tris(hydroxypyridinone) Derivatives
Peptide-based molecular imaging agents can rapidly accumulate at target tissue and clear from
circulation within 1–2 h. The 68 min half-life and positron emission properties of 68Ga (β+ 90%,
Emax = 1880 KeV) match these requirements for PET imaging of peptide receptor expression. Moreover,
68Ga is conveniently vailable by elution of the 68Ge/68Ga generat r to produce no-carrier-added
solutions of 68Ga3+ in hydrochloric acid [58].
Hydrated Ga3+ species such as [Ga(H2O)6]3+ exist in aqueous solution below pH 4. As the pH
is raised above 4, the poorly soluble hydroxide species Ga(OH)3 predominates in solution, until
pH > 6.3, where tetradentate [Ga(OH)4]− predominates [59,60]. For efficient 68Ga3+ radiolabelling
of chelat -peptide conjugates at neutral or near neu ral pH, chelate complex f r tion must
effectiv ly compete with unreactive 68Ga-colloid formation. Pr erably, the rate of chelation will be
diffusion-controlled, so that complex formation outcompetes 68Ga3+ colloid formation. Additionally,
the amounts of 68Ga eluted from clinical generators are in the range of 200–2000 MBq, approximately
equivalent to 2–20 pmol of 68Ga3+ in 1–5 mL of solution. Highly efficient chelators are required to
quantitatively complex such low concentrations of metal ion without using excessively high chelator
concentration. In clinical formulations of chelator bioconjugates, low concentrations of chel or-peptide
conjugate are important. Clinical formulations do not usually separate unlabelled bioconjugate from
labelled conjugate, and large amounts of unlabelled conjugate can lead to saturation of target receptors
in vivo.
As THP ligands have extraordinarily high pFe3+ values, and Ga3+ has similar coordination
preferences to Fe3+, it was reas ned that such chelators could be very efficient at q antitatively
coordinati g 68Ga3+ at low chelator concentrations [13]. The acyclic na ure of THP, a d hence flexibility
compared to macrocyclic ligands, results in low activation barriers to complexation, resulting in rapid
rates of reaction at room temperature.
It is also critical that the 68Ga3+ complex is sufficiently kinetically stable over the period of time
required for imaging (1–2 h) to withstand transchelation by competing endogenous proteins, such as
transferrin, and other ligands that c mpete for G 3+ in vivo [4]. The iron transport protein transferrin
is abundant in rum and its two metal binding sites hav high affinity for Fe3+ (log β1 = 22.8,
log β2 = 44.3) and Ga3+ (log β1 = 20.3, log β2 = 39.6) [61]. Transchelation of 68Ga3+ to endogenous
ligands results in increased non-target tissue uptake and lower tumour/diseased tissue uptake,
decreasing PET image quality.
As 3,4-HP and THP derivatives can bind Fe3+ under physiological conditions, with the resulting
complexes excreted, it was hypothesised that a THP Ga3+ complex could be sufficiently stable in vivo.
Mouse biodistribution studies with the γ-emitting isotope, 67Ga3+ (half-life = 78 h), comparing
the biodistribution of [67Ga(deferiprone)3] with [67Ga(citrate)3] show that mice administered the
deferiprone complex intravenously have lower 67Ga blood activity one day post-administration than
animals administered the citrate complex [37]. Subsequent studies demonstrate that 67Ga: (i) clears
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more rapidly from animals administered the deferiprone complex compared to animals administered
the citrate complex; and (ii) clears predominantly via a renal pathway in animals administered
the deferiprone complex [37,62]. N1-functionalised derivatives of 3,4-HP are also efficacious at
sequestering 67Ga3+ in vivo, with biodistribution of radioactivity modified by N1 substituents [62].
Such results suggest that [67Ga(deferiprone)3] has appreciable stability in vivo, and that 3,4-HPs can
effectively compete with endogenous protein ligands for Ga3+ [37,62].
5.2. Tris(hydroxypyridinone) Bioconjugates
We first reported the utility of THP-Ac (26, Figure 8) as a basis for highly efficient 68Ga
labelling under very mild conditions after undertaking side-by-side comparisons of THP-Ac
with chelators already commonly used to complex 68Ga3+: macrocyclic derivatives DOTA (41)
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and NOTA (42) (1,4,7-triazacyclononane-1,4,7-
triacetic acid), and the acyclic chelator HBED (43) (bis(2-hydroxybenzyl)ethylenediaminediacetic acid)
(Figure 9) [13]. Each chelator was reacted with generator-produced 68Ga3+ at progressively lower
chelator concentrations (100 nM–1 mM, each 100 µL corresponding to amounts of 10 pmol–100 nmol)
(Figure 10), with the reasoning that the most efficient, rapidly complexing chelators would maintain
high labelling efficiency at the lowest ligand concentrations. Optimised reaction conditions (as reported
in the radiochemical literature) for each chelator were employed. At a concentration of 10 µM, THP-Ac
complexes 68Ga3+ in 5 min in >98% radiochemical yield at pH 6.5 at room temperature. Radiochemical
yields for DOTA are >95% at the same chelator concentration, but this requires heating at 100 ◦C
at pH 4.4. NOTA has been reported to coordinate 68Ga3+ efficiently at room temperature, but at
10 µM concentration at room temperature, pH 4.4, radiochemical yields only average 80%. At 10 µM,
HBED is able to complex 68Ga3+ in >96% radiochemical yield at pH 4.6. Whilst HBED radiochemical
yields under acidic conditions are comparable to those of THP-Ac at near neutral pH, HBED forms
geometric isomers when complexed to Ga3+ [4]. From a regulatory perspective, the presence of
different geometric isomers is undesirable, as it is possible that the different isomers have different
pharmacological profiles.
Int. J. Mol. Sci. 2017, 18, 116 12 of 23 
 
administered the citrate complex; and (ii) clears predominantly via a renal pathway in animals 
administered the deferiprone complex [37,62]. N1-functionalised derivatives of 3,4-HP are also 
efficacious at sequestering 67Ga3+ in vivo, with biodistribution of radioactivity modified by N1 
substituents [62]. Such results suggest that [67Ga(deferiprone)3] has appreciable stability in vivo, and 
that 3,4-HPs can effectively compete with endogenous protein ligands for Ga3+ [37,62]. 
5.2. Tris(hydroxypyridinone) Bioconjugates 
We first reported the utility of THP-Ac (26, Figure 8) as a basis for highly efficient 68Ga  
labelling under very mild conditions after undertaking side-by-side comparisons of THP-Ac with 
chelators already commonly used to complex 68Ga3+: macrocyclic derivatives DOTA (41) (1,4,7,10- 
tetraazacyclododecane-1,4,7,10-tetraacetic acid) and NOTA (42) (1,4,7-triazacyclononane-1,4,7- 
triacetic acid), and the acyclic chelator HBED (43) (bis(2-hydroxybenzyl)ethylenediaminediacetic 
acid) (Figure 9) [13]. Each chelator was reacted with generator-produced 68Ga3+ at progressively 
lower helator concentrations (100 nM–1 mM, each 100 µL corresponding to amou ts of 10 
pmol–100 nmol) (Figure 10), with the reasoning that the most efficient, rapidly complexing chelators 
would maintain high labelling efficiency at the lowest ligand concentrations. Optimised reaction 
conditions (as reported in the radiochemical literature) for each chelator were employed. At a 
concentration of 10 µM, THP-Ac complexes 68Ga3+ in 5 min in >98% radiochemical yield at pH 6.5 at 
room temperature. Radiochemical yields for DOTA are >95% at the same chelator concentration, but 
this requires heating at 100 °C at pH 4.4. NOTA has been reported to coordinate 68Ga3+ efficiently at 
room temperature, but at 10 µM concentration at room temperature, pH 4.4, radiochemical yields 
only average 80%. At 10 µM, HBED is able to complex 68Ga3+ in >96% radiochemical yield at p  4.6. 
Whilst HBED radiochemical yields under acidic conditions are comparable to those of THP-Ac at 
near neutral pH, HBED forms geometric isomers when complexed to Ga3+ [4]. From a regulatory 
perspective, the presence of different geometric isomers is undesirable, as it is possible that the 
different isomers have different pharmacological profiles. 
 
Figure 9. Chelators for 68Ga3+. 
 
Figure 10. Radiolabelling yield versus ligand concentration for 68Ga-DOTA (pH 4.4, 30 min, 100 °C), 
68Ga-NOTA (pH 3.6, 10 min, room temperature), 68Ga-HBED (pH 4.6, 10 min, room temperature) and 
68Ga-THP, (pH 6.5, 5 min, room temperature). All experiments were conducted with the same batch 
of 68Ga eluate. All radiolabelling buffers were 0.2 M acetic acid/sodium acetate. Reprinted with 
permission from Berry, D.J.; et al. Efficient bifunctional gallium-68 chelators for positron emission 
Figure 9. Chelators for 68Ga3+.
Int. J. Mol. Sci. 2017, 18, 116 12 of 23 
 
administered the citrate complex; and (ii) clears predominantly via a renal pathway in animals 
administered the deferiprone complex [37,62]. N1-functi alised erivatives of 3,4-HP are also 
efficacious at sequestering 67Ga3+ in vivo, with biodistribution of radioactivity modified by N1 
substituents [62]. Such results uggest that [67Ga(deferiprone)3] has appreciable stability in vivo, and 
that 3,4-HPs can effectively compete with endogenous protein ligands for Ga3+ [37,62]. 
5.2. Tris(hydroxypyridinone) Bioconjugates 
We first reporte  the utility of THP-Ac (26, Figure 8) as a basis f r highly efficient 68Ga  
labelling under very mild conditions after undertaking side-by-side comparison  f THP-Ac with 
chelators already commonly used to complex 68Ga3+: macrocyclic derivatives DOTA (41) (1,4,7,10- 
tetraazacyclododecane-1,4,7,10-tetraacetic acid) and NOTA (42) (1,4,7-triazacyclo onane-1,4,7- 
triacetic acid), and the acyclic chelator HBED (43) (bis(2-hydroxybenzyl)ethylenediaminediacetic 
acid) (Figure 9) [13]. Each chelator was reacted with generator-produced 68Ga3+ at progressively 
lower chelator concentrations (100 nM–1 mM, each 100 µL corresponding to amounts of 10 
pmol–100 nmol) (Figure 10), with the reasoning that the most efficient, rapidly co plexing chelators 
would maintain high labelling efficiency at the lowest ligand concentrations. Optimised reaction 
co ditions (as reported in the radiochemical literature) for each chelator were employed. At a 
conce tr ion f 10 µM, THP-Ac complexes 68Ga3+ in 5 min in >98% radiochemical yield at pH 6.5 at 
room temperature. Radiochemical yields for DOTA are >95% at the same chelator concentration, but 
this requires heating at 100 °C at pH 4.4. NOTA has been reported to coordinate 68Ga3+ efficiently at 
room temperature, but at 10 µM concentration at room temperature, pH 4.4, radiochemical yields 
only average 80%. At 10 µM, HBED is able to c mplex 68Ga3+ in >96% adiochemical yield at pH 4.6. 
Whilst HBED radiochemical yields under acidic co ditions are comparable to those of THP-Ac at 
near neutral H, HBED forms geometric isomers when complexed to Ga3+ [4]. From a regulatory 
perspective, t e presence of different geometric isomers is undesirable, as it is possible that the 
different isomers have different pharmacological profiles. 
 
Figure 9. Chelators for 68Ga3+. 
 
Figure 10. Radiolabelling yield versus ligand concentration for 68Ga-DOTA (pH 4.4, 30 min, 100 °C), 
68Ga-NOTA (pH 3.6, 10 min, room temperature), 68Ga-HBED (pH 4.6, 10 min, room temperature) and 
68Ga-THP, (pH 6.5, 5 min, room temperature). All experiments were conducted with the same batch 
of 68Ga eluate. All radiolabelling buffers were 0.2 M acetic acid/sodium acetate. Reprinted with 
permission from Berry, D.J.; et al. Efficient bifunctional gallium-68 chelators for positron emission 
Figure 10. Radiolabelling yield versus ligand concentration for 68Ga-DOTA (pH 4.4, 30 min, 100 ◦C),
68Ga-NOTA (pH 3.6, 10 min, room temp atu , 68G -HBED (pH 4.6, 10 min, roo temperature)
and 68Ga-THP, (pH 6.5, 5 min, room temperature). All experiments were conducted with the same
batch of 68Ga eluate. All radiolabelling buffers were 0.2 M acetic acid/sodium acetate. Reprinted with
permission from Berry, D.J.; et al. Efficient bifunctional gallium-68 chelators for positron emission
tomography: tris(hydroxypyridinone) ligands. Chem. Commun. 2011, 47, 7068–7070. Copyright Royal
Society of Chemistry.
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The β-alanine-derived compound, THP-NH2 (37) [51], can be functionalised for bioconjugation
via a maleimide [13,16] and isothiocyanates [14,15] (Figure 8). The bifunctional chelators THP-mal (38),
THP-Ph-NCS (39) and THP-NCS (40) have all been conjugated to biomolecules. Amide conjugation of
THP-NH2 (37) to activated carboxylates of peptides and proteins is also a viable conjugation strategy.
The protein C2A, containing an engineered cysteine residue, has been conjugated to THP-mal
(38), resulting in a single equivalent of THP-mal attached per protein molecule [13]. The conjugate
can be radiolabelled with 68Ga3+ at pH 5.5 (6 nmol of protein in 100 µL, at a concentration of 60 µM),
giving quantitative labelling after 5 min. In vivo PET imaging in healthy mice demonstrates that
68Ga-THP-mal-C2A clears to the kidneys, and does not release any 68Ga3+ over a 90 min period.
In contrast, in mice administered solutions of unchelated 68Ga3+, radioactivity is distributed throughout
the body 90 min post-injection. In competition studies where 68Ga-THP-Ac is incubated with
transferrin, [68Ga(THP-Ac)] remains intact. On the other hand, when 68Ga-transferrin is incubated
with THP-Ac, 68Ga is quickly transchelated to form a complex with THP-Ac [13].
THP-Ph-NCS and THP-NCS have both been attached to the cyclic pentapeptide, c(RGDfK) via
lysine sidechains [14]. The “RGD” peptide motif targets αvβ3 integrin receptors that are expressed on
the surface of many metastatic tumour cells, as well as inflamed tissue and blood vessels undergoing
angiogenesis. Both THP-Ph-NCS-RGD (41, Figure 11) and THP-NCS-RGD (42, Figure 11) can be
radiolabelled with generator-produced 68Ga3+ eluate at conjugate concentrations of 4–5 µM, or total
amounts of 10–12 nmol, giving radiochemical yields of 95%–99%. These reactions proceed in aqueous
solution, pH 5.5–6.5 in less than 5 min at ambient temperature to give a single product corresponding
to either [68Ga(THP-Ph-NCS-RGD)] or [68Ga(THP-NCS-RGD)].
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Figure 1 . Representative PET maxi um intensity pr jection of Balb/c nu/nu mice bearing
U87MG tumours on right flank at 1 h post-injection of: (a) [68Ga(THP-Ph-NCS-RGD)]; and
(b) [68Ga(THP-NCS-RGD)]. Black arrow, tumour; grey arrow, bladder; dashed arrow, kidneys
and liver. Reprinted with permission under a Creative Commons Attribution (CC-BY) License
from Ma, M.T.; et al. New tris(hydroxypyridinone) bifunctional chelators containing isothiocyanate
groups provide a versatile platform for rapid one-step labelling and PET imaging with 68Ga3+.
Bioconjugate Chem. 2016, 27, 309–318. Copyright American Chemical Society.
Both [68Ga(THP-Ph-NCS-RGD)] and [68Ga(THP-NCS-RGD)] retain affinity for αvβ3 integrin
receptors in vitro and in vivo [14]. PET imaging and biodistribution studies of mice bearing U87MG
Int. J. Mol. Sci. 2017, 18, 116 14 of 23
tumours demonstrate that both [68Ga(THP-Ph-NCS-RGD)] and [68Ga(THP-NCS-RGD)]: (i) selectively
target αvβ3 integrin receptors; and (ii) clear from the body within 1–2 h post-injection, predominantly
via a renal route (Figure 11).
The molecular imaging agent, [68Ga(DOTA-TATE)] is routinely used for PET imaging of
neuroendocrine tumours. DOTA-TATE (43, Figure 12) is a conjugate of the macrocyclic chelator
DOTA (27, Figure 9) and Tyr3-octreotate, an eight amino acid cyclic peptide that targets somatostatin
2 receptors (SSTR) overexpressed on the surface of neuroendocrine tumours. Using THP-NCS,
THP-TATE (44, Figure 12) has been synthesised [15]. Similar to RGD conjugates, THP-TATE can
be radiolabelled at room temperature at concentrations of 5 µM (10 nmol of conjugate) at near
neutral pH in less than 2 min. In contrast, DOTA-TATE requires temperatures of 80–90 ◦C at
pH 3–5, with reaction times of 5–10 min, and in clinical radiolabelling protocols, post-synthetic
purifications procedures are invariably employed [15]. PET imaging and biodistribution experiments
show that [68Ga(THP-TATE)] has similar uptake in SSTR-positive tumours to the clinical standard
[68Ga(DOTA-TATE)]. [68Ga(THP-TATE)] clears via a renal pathway, but significantly higher kidney
and liver retention of [68Ga(THP-TATE)] is observed (Figure 12). In PET images of mice bearing
SSTR2-positive tumours administered [68Ga(THP-TATE)], tumours can be clearly delineated.
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Commons Attribution (CC-BY) License from Ma, M.T.; et al. Rapid kit-based 68Ga-labelling and PET
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5.3. Preparation, Radiolabelling and In itro ptake of a Trastuzu ab I unoconjugate
e protein constructs that target receptors with high affinity and specificity have similar utility
to peptides in molecular imaging. For proteins with short circulation times and rapid accumulation
at target tissue, 68Ga PET imaging will be clinically viable, provided that appropriate radiolabelling
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protocols are available. The sensitivity of proteins’ tertiary structures to acidic pH and extremes of
temperature requires mild radiolabelling conditions, raising problems when using conventional Ga3+
chelators. HBED, NOTA and DFO are capable of radiolabelling Ga3+ isotopes at room temperature, but
HBED [63] and NOTA [64] require low pH for reactions to proceed quantitatively, and DFO complexes
of Ga3+ are unstable [65].
Trastuzumab is a therapeutic monoclonal antibody used for treatment of breast cancer. It targets
the human epidermal growth factor receptor 2 (HER2). In vivo, antibodies such as trastuzumab
require extended periods of time (6 to 48 h) to clear circulation and accumulate at HER2-positive target
tissue, and given the short half-life of 68Ga, it is likely impractical to use 68Ga-labelled trastuzumab
to image HER2 expression. Nonetheless, it is instructive to radiolabel THP-PhNCS-trastuzumab
to assess whether a THP protein conjugate that is sensitive to acidic pH (less than pH 5) can be
radiolabelled rapidly under mild conditions (pH 6–7) to provide a formulation suitable for injection
without further purification.
The bifunctional chelator THP-PhNCS has been conjugated to the monoclonal antibody (mAb),
trastuzumab by incubating a HEPES buffered solution containing both reagents under mild
conditions [66,67]. The immunoconjugate, THP-PhNCS-trastuzumab has been isolated using solid
phase size exclusion chromatography [66,67]. Addition of generator-produced 68Ga3+ (~10 MBq,
50 µL, aqueous 0.1 M HCl) to solutions of THP-PhNCS-trastuzumab (50 µL, 0.65 mg·mL−1, 0.2 M
ammonium acetate, pH 6–7) results in formation of [68Ga(THP-PhNCS-trastuzumab)], with specific
activities of up to 50 MBq·nmol−1 and radiochemical yields of 99% as measured by size exclusion
HPLC (Figure 13a, red trace). The major signal at 7.98 min in the radiochromatogram matches the
retention time of native trastuzumab, and the minor signal at 6.83 min is typical of formation of
radiolabelled immunoconjugate aggregates [66]. Addition of 68Ga3+ solutions to samples containing
native, unconjugated trastuzumab do not provide labelled antibody (Figure 13a, black trace)—the
mobile phase in these experiments contains ethylenediaminetetraacetate (EDTA), and the single signal
in the radiochromatogram with a retention time of 12.08 min corresponds to [68Ga(EDTA)]−.
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Figure 13. (a) Size exclusion radio-HPLC traces of [68Ga(THP-PhNCS-trastuzumab)] (red)
and [68Ga(EDTA)]− (black); and (b) In vitro uptake of [68Ga(THP-PhNCS-trastuzumab)] and
[68Ga(THP-PhNCS-trastuzumab)] in the presence of an inhibitory concentration of trastuzumab, and
68Ga3+ in HER2-positive HCC1954 cells, and [68Ga(THP-PhNCS-trastuzumab)] in HER2-negative
A375 cells, after 30 min incubation. Uptake is expressed as a percentage of added radioactivity
(AR)/1 × 106 cells (n = 3, error bars correspond to standard error of the mean).
Int. J. Mol. Sci. 2017, 18, 116 16 of 23
To establish that the labelled immunoconjugate, [68Ga(THP-PhNCS-trastuzumab)], retains
affinity for HER2 receptors, [68Ga(THP-PhNCS-trastuzumab)] has been incubated with HER2-positive
HCC1954 cells and HER2-negative A375 cells. Additionally, a blockade experiment where
[68Ga(THP-PhNCS-trastuzumab)] is incubated with HCC1954 cells in the presence of a large excess of
native trastuzumab has been undertaken. Uptake of [68Ga(THP-PhNCS-trastuzumab)] in HCC1954 cells
measures 35.12± 0.53 percentage of added radioactivity per one million cells (%AR/million cells), whereas
uptake in A375 cells measures 1.98%± 0.02 %AR/million cells and uptake in the trastuzumab blockade
measures 0.30% ± 0.03 %AR/million, indicating that uptake of [68Ga(THP-PhNCS-trastuzumab)] is
receptor-mediated, and that in vitro [68Ga(THP-PhNCS-trastuzumab)] retains affinity for HER2-expressing
cells (Figure 13b). Addition of a solution containing 68Ga3+ to HCC1954 cells does not result in
significant uptake of activity (1.09% ± 0.05 %AR/million cells).
Thus, THP enables efficient and rapid 68Ga3+ radiolabelling of proteins under mild, aqueous
conditions. This radiolabelling strategy will have utility for 68Ga PET imaging of proteins such as
fusion proteins and antibody fragments that have shorter clearance times than full length antibodies.
5.4. Other THP Derivatives
Alternative THP chelators such as NTP(PrHP)3 (45) have been reported for complexation of
the SPECT isotope, 67Ga [68,69]. In these derivatives (Figure 14), the 3,4-HP groups are attached
to the tripodal scaffold via the N1 ring atoms, and the chelating O atoms are meta and para to the
linker. Such a topology can lead to formation of either dinuclear structures or structures where one
3,4-HP unit has dissociated [55]. Both species are generally more kinetically labile than species of
a 1:1 stoichiometry and are not ideal for in vivo applications. The presence of more than one complex
structure is also undesirable, as these species can have different biological behaviours. NTP(PrHP)3,
with its tripodal topology centred on a tertiary amine rather than carbon, is not readily adapted to use
as a bifunctional chelator. SPECT imaging and biodistribution studies with 67Ga3+ indicate that most
[67Ga-NTP(PrHP)3] rapidly clears circulation within 1 h, and remaining [67Ga-NTP(PrHP)3] does not
release 67Ga3+ over 24 h [69].
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6. Hydroxypyridinones for Radiolabelling 89Zr4+
We have also investigated THP-Ac and a THP-mal-trastuzumab conjugate for radiolabelling with
the long-lived PET isotope, zirconium-89 (89Zr4+) (half-life = 78 h) [16]. The Zr4+ ion is oxophilic, and
bifunctional hexadentate DFO derivatives are most commonly utilised for incorporating 89Zr4+ into
antibodies. There is evidence that [89Zr(DFO)]+ derivatives are unstable in vivo, with observations of
Int. J. Mol. Sci. 2017, 18, 116 17 of 23
89Zr accumulation in the skeleton over the course of a week [16]. Here, skeletal uptake is assumed to
be indicative of dissociation of 89Zr4+ from a chelator-conjugate.
Both THP-Ac and THP-mal-trastuzumab can be radiolabelled with 89Zr4+ at room temperature
and near neutral pH in quantitative yield. For THP-Ac, this was achieved at 1 mM concentration
and 10 µL volume, corresponding to 10 nmol of ligand. Competition experiments indicated
a thermodynamic preference for Zr4+ coordination to THP-Ac over DFO. This is consistent with
higher metal ion affinities of 3,4-HPs compared to hydroxamates. However, experiments in
which 89Zr-THP-mal-trastuzumab was administered to healthy animals indicate that in vivo, 89Zr4+
dissociates from THP-mal-trastuzumab within 48 h, with activity accumulating in the skeleton
(Figure 15). In vivo stability of the [89Zr(THP)]+ complex is inferior to that of the [89Zr(DFO)]+
complex, possibly a result of the different chelator topologies.
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[89Zr(ox)4]4− 98% of the injected dose remains 4 h post-injection, and is associated predominantly with 
the skeleton. For the animal administered 89Zr-THP-mal-trastuzumab, the skeleton is clearly visible 
from three days post-injection, indicative of dissociation of 89Zr4+ from THP-mal-trastuzumab over 
time. This is in marked contrast to the animal administered 89Zr-DFO-trastuzumab, where the blood 
pool remains visible out to seven days post-injection. Reprinted with permission under a Creative 
Commons Attribution (CC-BY) License from Ma, M.T.; et al. Tripodal tris(hydroxypyridinone) 
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Figure 15. PET scans of C57Bl/6j mice administered: (a) [89Zr(oxalate)4]4−;
(b) 89Zr-THP-mal-trastuzumab; and (c) 89Zr-DFO-mal-trastuzumab. For the animal administered
[89Zr(ox)4]4− 98% of the injected dose remains 4 h post-injection, and is associated predominantly with
the skeleton. For the animal administered 89Zr-THP-mal-trastuzumab, the skeleton is clearly visible
from three days post-injection, indicative of dissociation of 89Zr4+ from THP-mal-trastuzumab over
time. This is in marked contrast to the animal administered 89Zr-DFO-trastuzumab, where the blood
pool remains visible out to seven days post-injection. Reprinted with permission under a Creative
Commons Attribution (CC-BY) License from Ma, M.T.; et al. Tripodal tris(hydroxypyridinone) ligands
for immunoconjugate PET imaging with 89Zr4+: comparison with desferrioxamine-B. Dalton Trans.
2015, 44, 4884–4900. Copyright Royal Society of Chemistry.
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Zr4+ can accommodate up to eight donor atoms in its coordination sphere, and these coordination
requirements are likely to be a factor in the instability of [89Zr(THP)]+ in vivo. The presence of
two coordination sites unoccupied by THP chelator allows coordination of endogenous ligands, and
provides pathways to transmetallation/ligand exchange.
It is possible that a tetrakis(3,4-hydroxypyridinone) ligand could impart greater in vivo
stability, but there are no reports of such ligands to date. Other researchers have studied
octadentate tetrakis(hydroxypyridinone) derivatives for 89Zr4+ incorporating 1,2-HPs and 3,2-HPs.
The bifunctional open chain (1,2-HP)4 chelator (46, Figure 16) can: (i) coordinate Zr4+ in an octadentate
environment; and (ii) be conjugated to trastuzumab. Immunoconjugate (1,2-HP)4-trastuzumab can
be radiolabelled with 89Zr4+ at room temperature, and PET imaging and biodistribution studies
demonstrate high in vivo stability of the complex, with concomitant high tumour uptake [70].
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defined, and chromatographic analysis indicates that multiple Zr-bound (3,2-HP)4 species form 
under the mild reaction conditions described (room temperature, 15 min incubation). PET imaging 
and biodistribution studies in mice using 89Zr-labelled (3,2-HP)4-antibody conjugates suggest that at 
least one form of 89Zr4+-(3,2-HP)4 is unstable in vivo, as significantly higher bone uptake is observed 
for (3,2-HP)4 conjugates compared to DFO conjugates. This highlights the difficulty in interpreting in 
vivo results based on radiolabelled compounds that contain metal complexes in more than one 
conformation. 
7. Concluding Remarks 
Derivatisation of 3,4-HPs via substitution of ring protons allows for tailoring of chelator 
properties including the proton and Fe3+ affinities, and in vivo distribution and reactivity towards 
endogenous enzymes. 3,4-HPs can be further functionalised with fluorescent tags and biologically 
active motifs, and can be incorporated into chelators of higher denticity. Hexadentate THP chelators 
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Bifunctional macrobicyclic octadentate (3,2-HP)4 (47, Figure 16) has also been derivatised for
conjugation to trastuzumab [71]. The coordination environment of the Zr4+ complex is not well defined,
and chromatographic analysis indicates that multiple Zr-bound (3,2-HP)4 species form under the mild
reaction conditions described (room temperature, 15 min incubation). PET imaging and biodistribution
studies in mice using 89Zr-labelled (3,2-HP)4-antibody conjugates suggest that at least one form of
89Zr4+-(3,2-HP)4 is unstable in vivo, as significantly higher bone uptake is observed for (3,2-HP)4
conjugates compared to DFO conjugates. This highlights the difficulty in interpreting in vivo results
based on radiolabelled compounds that contain metal complexes in more than one conformation.
7. Concluding Remarks
Derivatisation of 3,4-HPs via substitution of ring protons allows for tailoring of chelator properties
including the proton and Fe3+ affinities, and in vivo distribution and reactivity towards endogenous
enzymes. 3,4-HPs can be further functionalised with fluorescent tags and biologically active motifs,
and can be incorporated into chelators of higher denticity. Hexadentate THP chelators based on
3,4-HPs possess extraordinarily high pFe3+ values, and are very potent Fe3+ scavengers. As Fe3+ and
Ga3+ have similar coordination preferences, THP chelators are ideal candidates for development of
PET radiopharmaceuticals based on 68Ga3+, and direct translation of this chemistry has enabled rapid
development of bioconjugates of THP chelators for 68Ga PET imaging.
Simplicity of radiolabelling with minimal need for complex equipment and radiochemical
expertise is likely to be a key to the wider availability of 68Ga PET, and this is afforded by appropriate
design of a 68Ga chelator. THP derivatives fulfil these requirements whereas other established chelator
Int. J. Mol. Sci. 2017, 18, 116 19 of 23
designs do not. Current clinical radiosynthetic protocols based on DOTA and HBED derivatives
require heating (>80 ◦C), low pH (3–5) and post-synthetic purification/formulation. In contrast,
THP compounds can be radiolabelled and formulated by treatment with generator-produced 68Ga3+
in over 95% radiochemical yield under ambient conditions in less than 5 min, at low chelator
concentrations, neutral pH and in aqueous solution. There is no requirement for post-synthetic
purification or reformulation, as reactions are quantitative and components (solvents and buffers) are
physiologically compatible. Bifunctional THP derivatives enable a means of attachment to peptides
and proteins, and biological studies have demonstrated that the peptide radiotracers are stable
in vivo with respect to dissociation of the 68Ga-THP complex, retain affinity for target receptors
and clear rapidly from circulation. All of these characteristics make THP superlative for one-step
kit-based radiosynthesis.
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Abbreviations
Bn Benzyl
DFO Deferrioxamine B
EDTA Ethylenediaminetetraacetate
GIT Gastrointestinal tract
HER2 Human epidermal growth factor receptor 2
HP Hydroxypyridinone
HPLC High performance liquid chromatography
PET Positron Emission Tomography
RGD Cyclic RGDfK peptide
TATE Octreotate
THP Tris(hydroxypyridinone)
SSTR2 Somatostatin 2 receptor
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